Gene-Based Therapy for Brain Cancer: Promises and Challenges

Abstract

Brain cancer, including gliomas and other malignant tumors, represents a devastating and challenging disease with limited treatment options and poor prognosis. Conventional therapies such as surgery, radiation, and chemotherapy have shown limited success, necessitating the exploration of alternative approaches. Gene-based therapy has emerged as a promising frontier in precision medicine, leveraging our growing understanding of the genetic and molecular drivers underlying brain tumor development and progression. This paper provides an overview of recent advancements in gene-based therapies for brain cancer, including gene editing techniques, gene silencing strategies, Immunotherapy, and more. Notably, these approaches aim to target specific oncogenes, tumor suppressor genes, and immune-related genes to inhibit tumor growth, induce apoptosis, and enhance the patient's immune response against cancer cells. Moreover, gene-based therapies offer the potential for personalized treatments tailored to individual patients based on their unique genetic profile, increasing treatment efficacy and minimizing adverse effects. While gene-based therapies have shown promising preclinical and early clinical results, challenges related to delivery, safety, and off-target effects remain to be addressed. This abstract emphasizes the urgent need for further research and large-scale clinical trials to establish the safety and long-term efficacy of gene-based therapies for brain cancer treatment. As the field continues to evolve, gene-based therapy holds great promise in reshaping the landscape of brain cancer management and providing hope for improved patient outcomes in the future.